Drug Trial Radar · NCT06742723
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5,000
Planned (sponsor's estimate)
Start
Mar 3, 2025
Primary completion
Dec 18, 2029
Study completion Dec 18, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
Conditions
- Chronic Kidney Disease and Hypertension
Interventions
Baxdrostat/dapagliflozinDrug
baxdrostat tablet dapagliflozin tablet
Placebo/dapagliflozinDrug
dapagliflozin tablet placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, Heart Failure events(HF), or CV death.Time frame: Up to 37 months
Locations
771 sites in 42 countries. Site status is shown where the registry gives one.
Research Site
Fairhope, Alabama · Recruiting
Research Site
Sun City, Arizona · Recruiting
Research Site
Tucson, Arizona · Recruiting
Research Site
Beverly Hills, California · Recruiting
Research Site
Canoga Park, California · Withdrawn
Research Site
Concord, California · Recruiting
Research Site
Fremont, California · Recruiting
Research Site
Fullerton, California · Recruiting
Research Site
Inglewood, California · Withdrawn
Research Site
Los Alamitos, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
San Diego, California · Withdrawn
Research Site
San Francisco, California · Withdrawn
Research Site
Stanford, California · Recruiting
Research Site
Tarzana, California · Recruiting
Research Site
Arvada, Colorado · Recruiting
Research Site
Denver, Colorado · Withdrawn
Research Site
New Britain, Connecticut · Recruiting
Research Site
Washington D.C., District of Columbia · Recruiting
Research Site
Boca Raton, Florida · Recruiting
Research Site
Boynton Beach, Florida · Recruiting
Research Site
Edgewater, Florida · Recruiting
Research Site
Fort Lauderdale, Florida · Recruiting
Research Site
Hollywood, Florida · Recruiting
Research Site
Jacksonville Beach, Florida · Recruiting
Research Site
Lake City, Florida · Recruiting
Research Site
Lakeland, Florida · Recruiting
Research Site
Melbourne, Florida · Recruiting
Research Site
Miami Lakes, Florida · Suspended
Research Site
Ocoee, Florida · Recruiting
Research Site
Port Charlotte, Florida · Recruiting
Research Site
Port Charlotte, Florida · Completed
Research Site
Port Orange, Florida · Recruiting
Research Site
Riverview, Florida · Recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Augusta, Georgia · Withdrawn
Research Site
Austell, Georgia · Recruiting
Research Site
Brunswick, Georgia · Recruiting
Research Site
Conyers, Georgia · Recruiting
Research Site
Decatur, Georgia · Recruiting
Showing 40 of 771 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.